The Royal Marsden Centre for Cancer Genomics has launched in London, becoming the first lab of its kind to deliver composite biomarker testing for NHS cancer patients across the UK. The new centre combines information about a patient and their tumour with artificial intelligence (AI) to build the fullest picture of a person’s cancer.
What composite biomarker testing means for patients
Composite biomarker testing involves taking multiple measurements from a patient during the course of their cancer treatment, including DNA, RNA and protein, and using AI to integrate the data into a score that tells doctors where the patient sits on a spectrum of treatment options. The findings will help doctors ensure NHS patients can access clinical trials, more personalised treatments, and flexible treatment plans that change as their cancer evolves.
Professor Michael Hubank, scientific director of clinical genomics at the Royal Marsden and professor of translational genomics at the Institute of Cancer Research, London, told the Press Association that his team is constantly thinking ahead to how cancer treatment and diagnostics will look in the next three to five years.
Professor Hubank on future treatment
“Currently, workflows in the NHS very much focus on doing a single test for a patient with a single action that follows it,” he said. “We think that, in the future, to really refine patient treatment to make sure that it’s truly a personalised treatment and personalised therapy and not just kind of a one-size-fits-all, we’ll be taking multiple measurements from patients during the course of treatment for cancer.”
He explained that AI will integrate the information to create a score that is very specific and tells doctors where that patient sits on a spectrum of how to treat them and what therapies to give them. Continuous monitoring will then tell doctors how to tailor treatment to each individual patient, whether that means giving them treatment breaks, coming off toxic drugs because they are responding well, or intensifying treatment if something has changed in the cancer.
Blood tests to monitor cancer return
Professor Hubank said he believes many more patients in the future will also be followed up with blood tests that look for tiny fragments of cancer in their bloodstream. Clinical trials have already shown positive results in using these circulating tumour DNA (ctDNA) blood tests to monitor patients to see whether their cancer is coming back.
Elaine Nangle, a 45-year-old from Wokingham, was diagnosed with stage 3 lobular breast cancer in March 2020, just as the country was going into Covid lockdown. She has three children – Freddie, 18, and twins Rory and Darcey, aged 16. Following her diagnosis, Ms Nangle was given a mastectomy and full node clearance to stop the cancer spreading, followed by six rounds of chemotherapy, 15 rounds of radiotherapy, and drugs to block oestrogen.
After initial treatment, Ms Nangle joined the TRAK-ER trial at the Royal Marsden, which gives patients a personalised circulating tumour DNA test every three months for up to three years. By looking for tiny fragments of tumour in the blood, doctors can detect whether cancer has returned way before the patient experiences any symptoms.
Patient experience
Ms Nangle told PA: “I had a stage three, grade two, 9cm tumour with lymph node involvement, so was quite panicked and had never really heard of tumours of that size. There isn’t any breast cancer in my family. There’s actually very little cancer in my family, it’s more heart disease. So when I rang home and said to my parents: ‘We’ve added a new one to the list, we’re now dealing with cancer as well,’ it was a bit of a shock for all of us. Also, I think I generally had associated a cancer diagnosis with an older person.”
Ms Nangle underwent treatment which has cleared her cancer but also plunged her into early menopause. Being on a clinical trial for circulating tumour DNA means doctors can keep a close eye on her to see whether the cancer is coming back. She said: “It’s always an interesting one that you don’t have scans at the end of treatment, and sometimes you can be left feeling a little bit: ‘How do I know? I didn’t realise I was sick in the first place, so how do I know I’m not sick again?’ It’s a hard thing to get your head around that kind of fear.”
In her most recent tests, she had an MRI scan which was all clear, and a mammogram which was also all clear. With the ctDNA blood test, she explained, they take a sample of her specific tumour and make a test that is bespoke to her. “You pop in, you have a blood test and within a couple of weeks, you get a phone call to say what’s happening. It offers a little bit of reassurance that everything is working well. Anything that gives me a greater chance of being here for longer, and being well for longer, is amazing.”
Expanding personalised treatment
Dr Angela George, clinical director of genomics and consultant medical oncologist at the Royal Marsden, said the new lab will also use expertise to assess all the new technologies coming on stream for genomics. She added: “The new centre will help make personalised treatment an option for more patients because we’ll be able to deliver more tests and look at new targets that we couldn’t previously do. Sometimes that will be about trialling new technology.”
She explained that this means they can look at blood samples where they used to have to look at pieces of tumour in order to get a test, which will be hugely important for patients where there is no solid tumour remaining, or where their disease is in places that cannot be accessed easily. It will also allow them to look much more carefully at things like patients having treatment breaks, by looking for tiny pieces of tumour in someone’s blood to see if there is still active cancer and if they need to continue treatment, or whether they have completely cleared the cancer at that point in time and can be given a break from treatment. “All of those types of things will be possible with the new laboratory.”
